Philips upgrades oncology platform for RT planning

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 7
Volume 18
Issue 7

Royal Philips Electronics introduced its third-generation Time-of-Flight platform for radiation oncology on its Gemini TF Big Bore PET/CT scanner at SNM 2009 in Toronto.

Royal Philips Electronics introduced its third-generation Time-of-Flight platform for radiation oncology on its Gemini TF Big Bore PET/CT scanner at SNM 2009 in Toronto. Time-of-flight technology measures the time difference between the detection of coincident gamma rays for accurate localization, producing a higher quality image and allowing for lower tracer dose amounts in patients and shorter imaging times, according to the company. The system has been installed at the proton therapy center at the University of Pennsylvania.

Articles in this issue
Letrozole appears less detrimental than tamoxifen to cognitive function in breast ca
Accelerated whole-breast irradiation does more with less after lumpectomy
RIBBON-1 results bolster bevacizumab as add-on to standard Rx for metastatic breast cancer
PET/CT Indicates if Early Neoadjuvant Rx is Making the Grade in Sarcoma Patients
Less is more when it comes to serial CA125 testing in ovarian cancer
Treatment varies widely in chronic myeloid leukemia
Should expectant management serve as the primary treatment option in prostate cancer?
Oncology takes blame for rising healthcare cost
Healthcare advocates call for universal coverage, acknowledge challenges
NSABP chair admits ‘failure’ in C-08 trial, denies defeat
Gemcitabine, capecitabine regimens equal in breast ca mets
Study ties survival to inflammatory markers in breast cancer
Canadians rally for national standards for breast ca testing
Trio of genes plays role in breast ca mets to brain
Micromet BiTE antibody eliminates leukemia cells

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content
The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

Linvoseltamab Receives EU Approval for Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
April 30th 2025
Article

The EU approval was based on results from the phase 1/2 LINKER-MM1 trial assessing the efficacy of linvoseltamab in relapsed/refractory multiple myeloma.

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

Elucidating Non-Invasive Radiosurgery Advancements in CNS Tumors

William R. Kennedy, MD
April 28th 2025
Podcast

A dedicated, well-trained, and expert staff at the Ivy Brain Tumor Center enables the facility to be at the forefront of cutting-edge radiosurgery treatment.

The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multi-Dose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

The CHMP Recommends Acalabrutinib Combos For Approval in Untreated CLL

Tim Cortese
April 30th 2025
Article

Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.

Cretostimogene Grenadenorepvec Displays Efficacy in BCG-Unresponsive NMIBC

Ashley Chan
April 29th 2025
Article

Complete response rates were observed consistently across patient subgroups in those with high-risk BCG-unresponsive non-muscle invasive bladder cancer.